PeptideDB

Betulinic acid (ALS357; Lupatic acid) 472-15-1

Betulinic acid (ALS357; Lupatic acid) 472-15-1

CAS No.: 472-15-1

Betulinic acid (also known as ALS-357; LS-357; Mairin; Lupatic acid; Betulic acid) is a naturally occuring pentacyclic t
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Betulinic acid (also known as ALS-357; LS-357; Mairin; Lupatic acid; Betulic acid) is a naturally occuring pentacyclic triterpenoid extracted from Syzigium claviflorum that displays anti-HIV and antitumor activity. Through an EC50 of 1.4 μ M, Betulinic acid inhibits HIV-1. By directly triggering the mitochondrial pathway of apoptosis in tumor cells in a way that is independent of both CD95 and p53, Betulinic acid specifically causes apoptosis in these cells. With an EC50 of 1.04 μM, Betulinic acid also exhibits TGR5 agonist activity.



Physicochemical Properties


Molecular Formula C30H48O3
Molecular Weight 456.7
Exact Mass 456.36
Elemental Analysis C, 78.90; H, 10.59; O, 10.51
CAS # 472-15-1
Related CAS #
472-15-1
PubChem CID 64971
Appearance White to off-white solid powder
Density 1.1±0.1 g/cm3
Boiling Point 550.0±33.0 °C at 760 mmHg
Melting Point 295-298 °C (dec.)(lit.)
Flash Point 300.5±21.9 °C
Vapour Pressure 0.0±3.4 mmHg at 25°C
Index of Refraction 1.533
LogP 8.94
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 3
Rotatable Bond Count 2
Heavy Atom Count 33
Complexity 861
Defined Atom Stereocenter Count 10
SMILES

O([H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]([H])(C1(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]1(C([H])([H])[H])[C@]2([H])C([H])([H])C([H])([H])[C@]2([H])[C@@]3([H])[C@]([H])(C(=C([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]3(C(=O)O[H])C([H])([H])C([H])([H])[C@@]12C([H])([H])[H]

InChi Key QGJZLNKBHJESQX-FZFNOLFKSA-N
InChi Code

InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
Chemical Name

(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
Synonyms

Lupatic acid; ALS357; ALS 357;Betulic acid; ALS-357; Mairin
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets Topoisomerase I ( IC50 = 5 μM ); HIV-1 ( IC50 = 1.4 μM ); NF-κB
ln Vitro

Betulinic acid is a eukaryotic topoisomerase I inhibitor that inhibits topoisomerase I-DNA interaction and has an IC50 of 5 μM[1]. MDA-MB-231 cell viability is significantly suppressed by betulinic acid (10, 20, 40, 80, and 160 μM) in a time- and dose-dependent manner following treatment for 24 or 48 hours. MDA-MB-231 cells express less Bcl-2 when exposed to betulinic acid (20, 40 μM). Additionally, betulinic acid alters the morphology of MDA-MB-231 cells at 20 μM and the ultrastructure of MDA-MB-231 cells at 40 μM[2]. With an EC50 of 1.4 μM in acutely infected H9 lymphocytes, betulinic acid exhibits anti-HIV activities[4].

ln Vivo
Betulinic acid (10 and 30 mg/kg, p.o.) blocks colon shortening and lowers lipid hydroperoxide and malondialdehyde (MDA) levels in mice with colitis brought on by dextran sulfate sodium (DSS). In mice with DSS-induced colitis, betulinic acid (30 mg/kg, p.o.) restores glutathione (GSH) levels, catalase activity, and superoxide dismutase (SOD) levels to normal. Additionally, betulinic acid (30 mg/kg, p.o.) prevents the rise in inflammatory markers brought on by DSS. Mice exposed to acetic acid (3, 10, 30 mg/kg, p.o.) or mustard oil (MO) do not exhibit writhing responses or visceral nociception.
Enzyme Assay The 25-mer annealed duplex consisting of oligonucleotide-1 and oligonicleotide-2 is subjected to an 8°C incubation period with 25 or 50 units of rat liver topoisomerase I, either in the presence or absence of betulinic acid in the binding buffer. Following incubation, the reaction mixtures are electrophoresed in a 7% non-denaturing polyacrylamide gel in 0.167 × TBE buffer at 4 °C. Ethidium bromide is then used to stain the DNA bands.
Cell Assay The assay makes use of CCK-8. After being grown at a density of 2 × 103 cells/well in 96-well plates, MDA-MB-231 cells are treated with DMSO vehicle or different concentrations of betulinic acid (5 µM to 160 µM) in 100 µL of medium for the specified durations. Following the treatment phase, 110 µL of medium containing 10 µL of the CCK-8 mixture is added to each well, and the plates are incubated at 37°C for one hour and thirty minutes. With the aid of a microplate reader, the absorbance at 450 nm wavelength is determined[2].
Animal Protocol
Oral betulinic acid (3, 10, or 30 mg/kg) or vehicle (5% v/v DMSO in peanut oil) is given to female Swiss albino mice. An observer who is blind to the treatments counts the number of writhing responses from each animal for 20 minutes after acetic acid (300 mg/kg) is given intraperitoneally after an hour. An animal exhibits a whining response when it rubs its belly on a table or floor while extending its hind limbs and body[3].
References

[1]. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002 Jul;8(7):BR254-65.

[2]. Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jan-Feb;42(1):49-54.

[3]. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec 26.

[4]. Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem. 1997 Dec;5(12):2133-43.

[5]. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005 Oct 20;24(46):6945-56.

Additional Infomation Betulinic acid is a pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-carboxy substituents. It is found in the bark and other plant parts of several species of plants including Syzygium claviflorum. It exhibits anti-HIV, antimalarial, antineoplastic and anti-inflammatory properties. It has a role as an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor, an anti-HIV agent, an antimalarial, an anti-inflammatory agent, an antineoplastic agent and a plant metabolite. It is a pentacyclic triterpenoid and a hydroxy monocarboxylic acid. It derives from a hydride of a lupane.
Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.
Betulinic acid has been reported in Paeonia emodi, Bowdichia virgilioides, and other organisms with data available.
Betulinic Acid is a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.
A lupane-type triterpene derivative of betulin which was originally isolated from BETULA or birch tree. It has anti-inflammatory, anti-HIV and antineoplastic activities.
See also: Paeonia lactiflora root (part of); Jujube fruit (part of).

Solubility Data


Solubility (In Vitro) DMSO: 20~35.7 mg/mL (43.8~78.2 mM)
Ethanol: 10 mg/mL (~21.9 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.08 mg/mL (4.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

Solubility in Formulation 2: 4 mg/mL (8.76 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.1896 mL 10.9481 mL 21.8962 mL
5 mM 0.4379 mL 2.1896 mL 4.3792 mL
10 mM 0.2190 mL 1.0948 mL 2.1896 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.